CHILDNEPH The Canadian Childhood Nephrotic Syndrome Study
NCT ID: NCT03786263
Last Updated: 2019-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2014-08-03
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease
NCT04591171
Fluid Balance, Hormones and Urine Proteomics in Nephrotic Syndrome in Childhood
NCT00690586
Steroid Treatment of Idiopathic Nephrotic Syndrome
NCT01386957
Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome
NCT01609426
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.
NCT06079788
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators are moving towards registry based trials to determine optimal treatment protocols for nephrotic syndrome with an overall goal to minimize glucocorticoid exposure, a patient priority.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospective Treatments for NS
Observation of children (between the ages of 1 and 17) who are diagnosed with Nephrotic Syndrome at their initial presentation, first or second relapse.
Observation of children who receive Glucocorticoids to treat Nephrotic Syndrome.
Observation of children who receive other drugs (Second Line Agents) for Nephrotic Syndrome.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Nephrotic Syndrome is secondary to other disease
* Younger than one year old or older than 17 years
1 Year
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susan Samuel, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alberta Children's Hospital
Calgary, Alberta, Canada
Stollery Children's Hospital, University of Alberta
Edmonton, Alberta, Canada
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Winnipeg Children's Hospital, University of Manitoba
Winnipeg, Manitoba, Canada
IWK Health Centre
Halifax, Nova Scotia, Canada
McMaster Children's Hospital
Hamilton, Ontario, Canada
Children's Hospital, London Health Sciences Centre
London, Ontario, Canada
Children's Hospital of Eastern Ontario (CHEO) University of Ottawa
Ottawa, Ontario, Canada
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada
CHU Ste. Justine
Montreal, Quebec, Canada
Montreal Children's Hospital - McGill University
Montreal, Quebec, Canada
Royal University Hospital, University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
James Tee, MD
Role: primary
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB13-0059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.